NCT03444753 2022-05-23An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedBristol-Myers SquibbPhase 1 Terminated82 enrolled